{"id":46162,"date":"2026-01-26T12:29:44","date_gmt":"2026-01-26T15:29:44","guid":{"rendered":"https:\/\/ocanal.com\/noticias\/corporativas\/samsung-epis-holdings-informa-resultados-financeiros-do-quarto-trimestre-e-do-ano-fiscal-de-2025\/"},"modified":"2026-01-26T12:29:44","modified_gmt":"2026-01-26T15:29:44","slug":"samsung-epis-holdings-informa-resultados-financeiros-do-quarto-trimestre-e-do-ano-fiscal-de-2025","status":"publish","type":"post","link":"https:\/\/ocanal.com\/noticias\/corporativas\/samsung-epis-holdings-informa-resultados-financeiros-do-quarto-trimestre-e-do-ano-fiscal-de-2025\/","title":{"rendered":"Samsung Epis Holdings informa resultados financeiros do quarto trimestre e do ano fiscal de 2025"},"content":{"rendered":"<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\">\nA Samsung Epis Holdings (KRX: 0126Z0), empresa de investimentos dedicada a inova\u00e7\u00f5es em biofarmac\u00eautica e biotecnologia, anunciou hoje seus resultados financeiros para o quarto trimestre e o ano fiscal de 2025.<\/p>\n<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\">\n&#8220;Estamos muito satisfeitos em anunciar um grande crescimento nas vendas no acumulado do ano, em nossos primeiros resultados financeiros ap\u00f3s a cis\u00e3o. Nosso crescimento org\u00e2nico foi impulsionado pelo s\u00f3lido desempenho de todo o nosso portf\u00f3lio de biossimilares&#8221;, disse Kyung-Ah Kim, Presidente e Diretora Executiva da Samsung Epis Holdings. &#8220;Continuamos fazendo progressos significativos em nossos marcos regulat\u00f3rios e comerciais com nosso portf\u00f3lio atual de biossimilares, enquanto investimos estrategicamente em nossa futura linha de produtos com um enfoque disciplinado e a longo prazo. Nossa meta \u00e9 impulsionar o crescimento sustent\u00e1vel e agregar valor a longo prazo a nossos acionistas, para que possamos manter nosso compromisso de melhorar o acesso dos pacientes em todo o mundo.&#8221;<\/p>\n<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\"><b>Resultados do quarto trimestre e do ano fiscal de 2025 da Samsung Bioepis<\/b><\/p>\n<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\">\nNo quarto trimestre de 2025, a Samsung Bioepis obteve uma receita consolidada de KRW 429,4 bilh\u00f5es e um lucro operacional de KRW 29,2 bilh\u00f5es. A receita e o lucro operacional com base nas vendas de produtos (excluindo a receita de marcos atingidos) no quarto trimestre aumentaram 23% e 14% em rela\u00e7\u00e3o ao mesmo per\u00edodo do ano anterior, respectivamente.<\/p>\n<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\">\nA receita do ano fiscal de 2025 alcan\u00e7ou KRW 1,672 trilh\u00e3o (+9%), enquanto o lucro operacional foi de KRW 375,9 bilh\u00f5es (-14%). Excluindo a receita referente a marcos atingidos, a receita de vendas e o lucro operacional foram de KRW 1,626 trilh\u00e3o (+28%) e KRW 330,8 bilh\u00f5es (+101%), respectivamente.<\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl\" xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\">\n<tr>\n<td class=\"bwpadl0 bwsinglebottom\" colspan=\"10\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n[Resultados consolidados, bilh\u00f5es de KRW]<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwrowaltcolor1\" colspan=\"2\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n\u00a0<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwrowaltcolor1 bwalignc bwvertalignm\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\"><b>4\u00baT 2023<\/b><\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwrowaltcolor1 bwalignc bwvertalignm\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\"><b>4\u00baT 2024<\/b><\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwrowaltcolor1 bwalignc bwvertalignm\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\"><b>4\u00baT 2025<\/b><\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwrowaltcolor1 bwalignc bwvertalignm\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\"><b>Varia\u00e7\u00e3o anual<\/b><\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwrowaltcolor1 bwalignc bwvertalignm\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\"><b>Ano fiscal 2023<\/b><\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwrowaltcolor1 bwalignc bwvertalignm\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\"><b>Ano fiscal 2024<\/b><\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwrowaltcolor1 bwalignc bwvertalignm\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\"><b>Ano fiscal 2025<\/b><\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwrowaltcolor1 bwalignc bwvertalignm\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\"><b>Varia\u00e7\u00e3o anual<\/b><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td colspan=\"2\" rowspan=\"1\" class=\"bwleftsingle bwrightsingle bwpadl0 bwsinglebottom bwvertalignm\">\n<p class=\"bwcellpmargin\"><b>Receita<\/b><\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwpadb3 bwalignc bwvertalignm\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\"><b>288,9<\/b><\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwpadb3 bwalignc bwvertalignm\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\"><b>397,4<\/b><\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwpadb3 bwalignc bwvertalignm\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\"><b>429,4<\/b><\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwalignc bwvertalignm\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\"><b>+32,0<sup>1<\/sup><\/b><\/p>\n<p class=\"bwalignc bwcellpmargin\">\n(+8%)<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwpadb3 bwalignc bwvertalignm\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\"><b>1.020,3<\/b><\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwpadb3 bwalignc bwvertalignm\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\"><b>1.537,7<\/b><\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwpadb3 bwalignc bwvertalignm\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\"><b>1.672,0<\/b><\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwalignc bwvertalignm\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\"><b>+134,3<sup>1<\/sup><\/b><\/p>\n<p class=\"bwalignc bwcellpmargin\">\n(+9%)<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n\u00a0<\/p>\n<\/td>\n<td colspan=\"1\" rowspan=\"1\" class=\"bwsinglebottom bwrightsingle bwpadl0 bwvertalignm\">\n<p class=\"bwalignc bwcellpmargin\">\nExcluindo receita de marcos atingidos<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwpadb3 bwalignc bwvertalignm\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n288,9<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwpadb3 bwalignc bwvertalignm\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n347,0<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwpadb3 bwalignc bwvertalignm\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n425,2<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwalignc bwvertalignm\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n+78,2<\/p>\n<p class=\"bwalignc bwcellpmargin\">\n(+23%)<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwpadb3 bwalignc bwvertalignm\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n1.008,3<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwpadb3 bwalignc bwvertalignm\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n1.266,8<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwpadb3 bwalignc bwvertalignm\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n1.626,9<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwalignc bwvertalignm\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n+360,1<\/p>\n<p class=\"bwalignc bwcellpmargin\">\n(+28%)<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td colspan=\"2\" rowspan=\"1\" class=\"bwleftsingle bwrightsingle bwpadl0 bwsinglebottom bwvertalignm\">\n<p class=\"bwcellpmargin\"><b>Lucro operacional<\/b><\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwpadb3 bwalignc bwvertalignm\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\"><b>78,2<\/b><\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwpadb3 bwalignc bwvertalignm\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\"><b>72,3<\/b><\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwpadb3 bwalignc bwvertalignm\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\"><b>29,2<\/b><\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwpadb3 bwalignc bwvertalignm\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\"><b>-43,1<\/b><\/p>\n<p class=\"bwcellpmargin bwalignc\">\n(-60%)<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwpadb3 bwalignc bwvertalignm\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\"><b>205,4<\/b><\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwpadb3 bwalignc bwvertalignm\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\"><b>435,4<\/b><\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwpadb3 bwalignc bwvertalignm\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\"><b>375,9<\/b><\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwpadb3 bwalignc bwvertalignm\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\"><b>-59,5<\/b><\/p>\n<p class=\"bwcellpmargin bwalignc\">\n(-14%)<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n\u00a0<\/p>\n<\/td>\n<td colspan=\"1\" rowspan=\"1\" class=\"bwsinglebottom bwrightsingle bwpadl0 bwvertalignm\">\n<p class=\"bwalignc bwcellpmargin\">\nExcluindo receita de marcos atingidos<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwpadb3 bwalignc bwvertalignm\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n78,2<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwpadb3 bwalignc bwvertalignm\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n21,9<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwpadb3 bwalignc bwvertalignm\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n25,0<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwalignc bwvertalignm\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n+3,1<\/p>\n<p class=\"bwalignc bwcellpmargin\">\n(+14%)<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwpadb3 bwalignc bwvertalignm\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n193,4<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwpadb3 bwalignc bwvertalignm\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n164,5<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwpadb3 bwalignc bwvertalignm\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n330,8<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwalignc bwvertalignm\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n+166,3<\/p>\n<p class=\"bwalignc bwcellpmargin\">\n(+101%)<\/p>\n<\/td>\n<\/tr>\n<\/table>\n<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\">\nO crescimento foi impulsionado pela cont\u00ednua expans\u00e3o mundial da Samsung Bioepis mediante lan\u00e7amentos de produtos, aprova\u00e7\u00f5es regulat\u00f3rias e novas parcerias.<\/p>\n<ul class=\"bwlistdisc\" xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\">\n<li>\nEPYSQLI\u2122 (SB12), um biossimilar ao Soliris<sup>2<\/sup> (eculizumabe), indicado para tratamento de Hemoglobin\u00faria Parox\u00edstica Noturna (PNH), S\u00edndrome Hemol\u00edtica Ur\u00eamica at\u00edpica (aHUS) e Miastenia Gravis generalizada (gMG), foi lan\u00e7ado nos EUA em abril de 2025 atrav\u00e9s de sua parceira de comercializa\u00e7\u00e3o, a Teva Pharmaceuticals, ampliando o acesso para pacientes com doen\u00e7as raras.<\/p>\n<\/li>\n<li>\nOBODENCE\u2122 \/ OSPOMYV\u2122<sup>3<\/sup> (SB16), um biossimilar ao Prolia<sup>4<\/sup> (denosumabe), e XBRYK\u2122 (SB16), um biossimilar ao Xgeva<sup>3<\/sup> (denosumabe), foram aprovados pela Food and Drug Administration (FDA) dos EUA e pela Comiss\u00e3o Europeia (CE) em fevereiro de 2025. Na Europa, o OBODENCE foi lan\u00e7ado em dezembro de 2025, seguido pelo lan\u00e7amento do XBRYK em janeiro de 2026. Em janeiro de 2026, quatro produtos s\u00e3o comercializados diretamente pela Samsung Bioepis na Europa: EPYSQLI (eculizumabe), OBODENCE (denosumabe), XBRYK (denosumabe) e BYOOVIZ\u2122 (ranibizumabe).<sup>5<\/sup><\/li>\n<li>\nPYZCHIVA\u2122 (SB17), um biossimilar ao Stelara<sup>6<\/sup> (ustequinumabe) foi lan\u00e7ado nos EUA em parceria com a Sandoz em fevereiro de 2025. O PYZCHIVA tamb\u00e9m est\u00e1 dispon\u00edvel como marca pr\u00f3pria desde o segundo e terceiro trimestres de 2025. No Jap\u00e3o, o SB17 foi aprovado como seringas para inje\u00e7\u00e3o subcut\u00e2nea de ustequinumabe BS 45 mg\u300cNIPRO\u300dpela Ag\u00eancia de Produtos Farmac\u00eauticos e Dispositivos M\u00e9dicos (PMDA) em dezembro de 2025. \u00c9 o primeiro produto a obter aprova\u00e7\u00e3o de comercializa\u00e7\u00e3o no Jap\u00e3o no \u00e2mbito da parceria com a NIPRO CORPORATION, assinada em junho de 2025.<\/p>\n<\/li>\n<li>\nA Samsung Bioepis firmou um contrato de parceria com a Harrow para comercializar o BYOOVIZ (SB11), um biossimilar que tem como refer\u00eancia o Lucentis<sup>7<\/sup> (ranibizumabe) e o OPUVIZ\u2122 (SB15), um biossimilar que faz refer\u00eancia ao Eylea<sup>8<\/sup> (aflibercepte), nos EUA.<\/p>\n<\/li>\n<\/ul>\n<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\"><b>Perspectivas para o ano fiscal de 2026<\/b><\/p>\n<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\">\nA Samsung Epis Holdings apoia ativamente os principais neg\u00f3cios de suas subsidi\u00e1rias sob a estrutura de holding, visando aumentar as vendas de biossimilares em mais de 10% em rela\u00e7\u00e3o ao ano anterior a n\u00edvel mundial. A Samsung Bioepis planeja garantir 20 biossimilares em seu portf\u00f3lio at\u00e9 2030, incluindo dupilumabe, guselcumabe, ixequizumabe, trastuzumabe deruxtecano, vedolizumabe e ocrelizumabe.<\/p>\n<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\">\nAl\u00e9m dos biossimilares, a empresa tamb\u00e9m iniciou o desenvolvimento de novas terapias. Ela planeja iniciar um novo candidato terap\u00eautico em estudo cl\u00ednico a cada ano, come\u00e7ando com o SBE303. O SBE303 \u00e9 o primeiro conjugado anticorpo-f\u00e1rmaco (ADC) da Samsung Bioepis elaborado para se ligar&agrave;Nectin-4, uma prote\u00edna de ades\u00e3o expressa especificamente em c\u00e9lulas tumorais, incluindo c\u00e2ncer de bexiga, c\u00e2ncer urotelial, c\u00e2ncer de pulm\u00e3o e c\u00e2ncer de mama.<sup>9<\/sup> O ensaio cl\u00ednico de fase 1, o primeiro em seres humanos, que visa avaliar a seguran\u00e7a, tolerabilidade, efic\u00e1cia, farmacocin\u00e9tica e imunogenicidade do SBE303 em participantes com tumores s\u00f3lidos avan\u00e7ados e refrat\u00e1rios, est\u00e1 previsto para come\u00e7ar este ano.<\/p>\n<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\">\nA Epis NexLab, nova subsidi\u00e1ria da Samsung Epis Holdings, lan\u00e7ou um projeto para desenvolver uma plataforma de administra\u00e7\u00e3o de medicamentos baseada em pept\u00eddeos.<\/p>\n<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\"><b>Sobre a Samsung Epis Holdings Co., Ltd.<\/b><\/p>\n<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\">\nComo uma holding de investimentos dedicada aos setores biofarmac\u00eautico e de biotecnologia, a Samsung Epis Holdings tem como objetivo maximizar o valor corporativo e para os acionistas por meio de P&amp;D e investimentos proativos, al\u00e9m de otimizar as estrat\u00e9gias de neg\u00f3cios de suas subsidi\u00e1rias, Samsung Bioepis e Epis NexLab. A Samsung Epis Holdings continua a abra\u00e7ar desafios futuros e a impulsionar a inova\u00e7\u00e3o ao identificar novos vetores de crescimento e fortalecer plataformas globais de colabora\u00e7\u00e3o, estabelecendo assim uma base s\u00f3lida para o crescimento cont\u00ednuo de suas subsidi\u00e1rias. Para mais informa\u00e7\u00f5es, acesse: <a href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.samsungepisholdings.com&amp;esheet=54403990&amp;newsitemid=20260125344665&amp;lan=pt-BR&amp;anchor=www.samsungepisholdings.com&amp;index=1&amp;md5=bf975a11abf121f8681212596f871306\" rel=\"follow\" shape=\"rect\" target=\"_blank\">www.samsungepisholdings.com<\/a>.<\/p>\n<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\"><b>Sobre a Samsung Bioepis Co., Ltd.<\/b><\/p>\n<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\">\nFundada em 2012, a Samsung Bioepis \u00e9 uma empresa biofarmac\u00eautica comprometida em tornar os cuidados de sa\u00fade acess\u00edveis a todos. Por meio de inova\u00e7\u00f5es no desenvolvimento de produtos e de um forte compromisso com a qualidade, a Samsung Bioepis busca se tornar a principal empresa biofarmac\u00eautica do mundo. A empresa continua a avan\u00e7ar um amplo pipeline de candidatos biol\u00f3gicos que abrangem diversas \u00e1reas terap\u00eauticas, incluindo imunologia, oncologia, oftalmologia, hematologia, nefrologia, neurologia e endocrinologia. Para mais informa\u00e7\u00f5es, acesse <a href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.samsungbioepis.com&amp;esheet=54403990&amp;newsitemid=20260125344665&amp;lan=pt-BR&amp;anchor=www.samsungbioepis.com&amp;index=2&amp;md5=40b3e190e9d99e21ad058cbdf587c231\" rel=\"follow\" shape=\"rect\" target=\"_blank\">www.samsungbioepis.com<\/a> e nos siga no <a href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fsamsungbioepis%2F&amp;esheet=54403990&amp;newsitemid=20260125344665&amp;lan=pt-BR&amp;anchor=LinkedIn&amp;index=3&amp;md5=8af0f886cc530be9e9651f99eab5f442\" rel=\"follow\" shape=\"rect\" target=\"_blank\">LinkedIn<\/a> e <a href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fx.com%2FSamsungBioepis&amp;esheet=54403990&amp;newsitemid=20260125344665&amp;lan=pt-BR&amp;anchor=X&amp;index=4&amp;md5=94754b74c55de23796ec6560dedd55f7\" rel=\"follow\" shape=\"rect\" target=\"_blank\">X<\/a>.<\/p>\n<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\"><b>Sobre a Epis NexLab Co., Ltd.<\/b><\/p>\n<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\">\nFundada em 2025 como subsidi\u00e1ria integral da Samsung Epis Holdings, a Epis NexLab dedica-se a impulsionar a inova\u00e7\u00e3o por meio do desenvolvimento de plataformas de biotecnologia de pr\u00f3xima gera\u00e7\u00e3o. Ao transformar tecnologias altamente escal\u00e1veis relacionadas a pept\u00eddeos em plataformas de desenvolvimento, a Epis NexLab est\u00e1 focada na descoberta de modalidades terap\u00eauticas inovadoras para o desenvolvimento de m\u00faltiplos candidatos terap\u00eauticos voltados a uma ampla gama de doen\u00e7as. Para mais informa\u00e7\u00f5es, acesse <a href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.samsungepisholdings.com&amp;esheet=54403990&amp;newsitemid=20260125344665&amp;lan=pt-BR&amp;anchor=www.samsungepisholdings.com&amp;index=5&amp;md5=64eb81f15f6448acd52401f0c39a2751\" rel=\"follow\" shape=\"rect\" target=\"_blank\">www.samsungepisholdings.com<\/a>.<\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl\" xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\">\n<tr>\n<td class=\"bwvertalignt bwpadl0 bwsinglebottom\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwtablemarginb bwblockalignl bwsinglebottom\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt\" colspan=\"1\" rowspan=\"1\"><sup>1<\/sup><\/td>\n<td class=\"bwpadl0 bwvertalignt\" colspan=\"2\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nA varia\u00e7\u00e3o anual (YoY) do lucro operacional reflete o &#8220;pagamento por etapas&#8221; \u2013 um sistema de pagamento que efetua o pagamento ap\u00f3s concluir etapas espec\u00edficas no desenvolvimento de um projeto.<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt\" colspan=\"1\" rowspan=\"1\"><sup>2<\/sup><\/td>\n<td class=\"bwpadl0 bwvertalignt\" colspan=\"2\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nSoliris \u00e9 uma marca registrada da Alexion Pharmaceuticals, Inc.<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt\" colspan=\"1\" rowspan=\"1\"><sup>3<\/sup><\/td>\n<td class=\"bwpadl0 bwvertalignt\" colspan=\"2\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nA SB16 foi aprovada sob diferentes nomes: OBODENCE na Europa e OSPOMYV nos EUA.<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt\" colspan=\"1\" rowspan=\"1\"><sup>4<\/sup><\/td>\n<td class=\"bwpadl0 bwvertalignt\" colspan=\"2\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nProlia e Xgeva s\u00e3o marcas registradas da Amgen Inc.<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt\" colspan=\"1\" rowspan=\"1\"><sup>5<\/sup><\/td>\n<td class=\"bwpadl0 bwvertalignt\" colspan=\"2\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nNa Europa, a Samsung Bioepis assumiu total responsabilidade pela comercializa\u00e7\u00e3o do BYOOVIZ ap\u00f3s a transfer\u00eancia dos direitos comerciais da Biogen de volta&agrave;Samsung Bioepis, com vig\u00eancia a partir de janeiro de 2026.<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt\" colspan=\"1\" rowspan=\"1\"><sup>6<\/sup><\/td>\n<td class=\"bwpadl0 bwvertalignt\" colspan=\"2\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nStellara \u00e9 uma marca registrada da Johnson &amp; Johnson Corporation.<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt\" colspan=\"1\" rowspan=\"1\"><sup>7<\/sup><\/td>\n<td class=\"bwpadl0 bwvertalignt\" colspan=\"2\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nLucentis \u00e9 uma marca registrada da Genentech Inc.<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt\" colspan=\"1\" rowspan=\"1\"><sup>8<\/sup><\/td>\n<td class=\"bwpadl0 bwvertalignt\" colspan=\"2\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nEylea \u00e9 uma marca registrada da Regeneron Pharmaceuticals, Inc.<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt\" colspan=\"1\" rowspan=\"1\"><sup>9<\/sup><\/td>\n<td class=\"bwpadl0 bwvertalignt\" colspan=\"2\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nLi K, Zhou Y, Zang M, Jin X, Li X. Perspectivas terap\u00eauticas da nectina-4 no c\u00e2ncer: aplica\u00e7\u00f5es e valor. Front Oncol. 2024 Mar 28;14:1354543. doi: 10.3389\/fonc.2024.1354543. PMID: 38606099; PMCID: PMC11007101.<\/p>\n<\/td>\n<\/tr>\n<\/table>\n<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\">\nO texto no idioma original deste an\u00fancio \u00e9 a vers\u00e3o oficial autorizada. As tradu\u00e7\u00f5es s\u00e3o fornecidas apenas como uma facilidade e devem se referir ao texto no idioma original, que \u00e9 a \u00fanica vers\u00e3o do texto que tem efeito legal.<\/p>\n<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\"><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260125344665r1&amp;sid=brdno&amp;distro=ftp\"><span class=\"bwct31415\"><\/span><\/p>\n<p id=\"mmgallerylink\" xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\"><span id=\"mmgallerylink-phrase\">Ver a vers\u00e3o original em businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20260125344665\/pt\/\" rel=\"follow\" target=\"_blank\">https:\/\/www.businesswire.com\/news\/home\/20260125344665\/pt\/<\/a><\/span><\/p>\n<p><b>Contato:<\/b><\/p>\n<p><b>Contato com a m\u00eddia<br \/>\n<\/b><\/p>\n<p>Yoon Kim, <a href=\"mailto:yoon1.kim@samsung.com\" rel=\"follow\" shape=\"rect\">yoon1.kim@samsung.com<br \/>\n<\/a><\/p>\n<p>Anna Nayun Kim, <a href=\"mailto:nayun86.kim@samsung.com\" rel=\"follow\" shape=\"rect\">nayun86.kim@samsung.com<\/a><\/p>\n<p><strong>Fonte: <\/strong><a href='http:\/\/www.businesswire.com\/portal\/site\/home\/' target='_blank'>BUSINESS WIRE<\/a><img src='https:\/\/api.dino.com.br\/v2\/news\/tr\/326508?partnerId=3197' alt=\"\" style=\"border:0px;width:1px;height:1px;\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>A Samsung Epis Holdings (KRX: 0126Z0), empresa de investimentos dedicada a inova\u00e7\u00f5es em biofarmac\u00eautica e biotecnologia, anunciou hoje seus resultados financeiros para o quarto trimestre e o ano fiscal de 2025. &#8220;Estamos muito satisfeitos em anunciar um grande crescimento nas vendas no acumulado do ano, em nossos primeiros resultados financeiros ap\u00f3s a cis\u00e3o. Nosso crescimento [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5],"tags":[],"class_list":["post-46162","post","type-post","status-publish","format-standard","hentry","category-noticias"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Samsung Epis Holdings informa resultados financeiros do quarto trimestre e do ano fiscal de 2025 - Ocanal Not\u00edcias Corporativas - Empresariais, comunicados e neg\u00f3cios<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ocanal.com\/noticias\/corporativas\/samsung-epis-holdings-informa-resultados-financeiros-do-quarto-trimestre-e-do-ano-fiscal-de-2025\/\" \/>\n<meta property=\"og:locale\" content=\"pt_BR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Samsung Epis Holdings informa resultados financeiros do quarto trimestre e do ano fiscal de 2025 - Ocanal Not\u00edcias Corporativas - Empresariais, comunicados e neg\u00f3cios\" \/>\n<meta property=\"og:description\" content=\"A Samsung Epis Holdings (KRX: 0126Z0), empresa de investimentos dedicada a inova\u00e7\u00f5es em biofarmac\u00eautica e biotecnologia, anunciou hoje seus resultados financeiros para o quarto trimestre e o ano fiscal de 2025. &#8220;Estamos muito satisfeitos em anunciar um grande crescimento nas vendas no acumulado do ano, em nossos primeiros resultados financeiros ap\u00f3s a cis\u00e3o. Nosso crescimento [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ocanal.com\/noticias\/corporativas\/samsung-epis-holdings-informa-resultados-financeiros-do-quarto-trimestre-e-do-ano-fiscal-de-2025\/\" \/>\n<meta property=\"og:site_name\" content=\"Ocanal Not\u00edcias Corporativas - Empresariais, comunicados e neg\u00f3cios\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-26T15:29:44+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260125344665r1&amp;sid=brdno&amp;distro=ftp\" \/>\n<meta name=\"author\" content=\"DINO\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"DINO\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. tempo de leitura\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/ocanal.com\\\/noticias\\\/corporativas\\\/samsung-epis-holdings-informa-resultados-financeiros-do-quarto-trimestre-e-do-ano-fiscal-de-2025\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ocanal.com\\\/noticias\\\/corporativas\\\/samsung-epis-holdings-informa-resultados-financeiros-do-quarto-trimestre-e-do-ano-fiscal-de-2025\\\/\"},\"author\":{\"name\":\"DINO\",\"@id\":\"https:\\\/\\\/ocanal.com\\\/noticias\\\/corporativas\\\/#\\\/schema\\\/person\\\/24f7b50e924d81f1023b69582993c0ff\"},\"headline\":\"Samsung Epis Holdings informa resultados financeiros do quarto trimestre e do ano fiscal de 2025\",\"datePublished\":\"2026-01-26T15:29:44+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/ocanal.com\\\/noticias\\\/corporativas\\\/samsung-epis-holdings-informa-resultados-financeiros-do-quarto-trimestre-e-do-ano-fiscal-de-2025\\\/\"},\"wordCount\":1372,\"image\":{\"@id\":\"https:\\\/\\\/ocanal.com\\\/noticias\\\/corporativas\\\/samsung-epis-holdings-informa-resultados-financeiros-do-quarto-trimestre-e-do-ano-fiscal-de-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260125344665r1&amp;sid=brdno&amp;distro=ftp\",\"articleSection\":[\"Not\u00edcias Corporativas\"],\"inLanguage\":\"pt-BR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/ocanal.com\\\/noticias\\\/corporativas\\\/samsung-epis-holdings-informa-resultados-financeiros-do-quarto-trimestre-e-do-ano-fiscal-de-2025\\\/\",\"url\":\"https:\\\/\\\/ocanal.com\\\/noticias\\\/corporativas\\\/samsung-epis-holdings-informa-resultados-financeiros-do-quarto-trimestre-e-do-ano-fiscal-de-2025\\\/\",\"name\":\"Samsung Epis Holdings informa resultados financeiros do quarto trimestre e do ano fiscal de 2025 - Ocanal Not\u00edcias Corporativas - Empresariais, comunicados e neg\u00f3cios\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ocanal.com\\\/noticias\\\/corporativas\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/ocanal.com\\\/noticias\\\/corporativas\\\/samsung-epis-holdings-informa-resultados-financeiros-do-quarto-trimestre-e-do-ano-fiscal-de-2025\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/ocanal.com\\\/noticias\\\/corporativas\\\/samsung-epis-holdings-informa-resultados-financeiros-do-quarto-trimestre-e-do-ano-fiscal-de-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260125344665r1&amp;sid=brdno&amp;distro=ftp\",\"datePublished\":\"2026-01-26T15:29:44+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/ocanal.com\\\/noticias\\\/corporativas\\\/#\\\/schema\\\/person\\\/24f7b50e924d81f1023b69582993c0ff\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/ocanal.com\\\/noticias\\\/corporativas\\\/samsung-epis-holdings-informa-resultados-financeiros-do-quarto-trimestre-e-do-ano-fiscal-de-2025\\\/#breadcrumb\"},\"inLanguage\":\"pt-BR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/ocanal.com\\\/noticias\\\/corporativas\\\/samsung-epis-holdings-informa-resultados-financeiros-do-quarto-trimestre-e-do-ano-fiscal-de-2025\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\\\/\\\/ocanal.com\\\/noticias\\\/corporativas\\\/samsung-epis-holdings-informa-resultados-financeiros-do-quarto-trimestre-e-do-ano-fiscal-de-2025\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260125344665r1&amp;sid=brdno&amp;distro=ftp\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260125344665r1&amp;sid=brdno&amp;distro=ftp\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/ocanal.com\\\/noticias\\\/corporativas\\\/samsung-epis-holdings-informa-resultados-financeiros-do-quarto-trimestre-e-do-ano-fiscal-de-2025\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"In\u00edcio\",\"item\":\"https:\\\/\\\/ocanal.com\\\/noticias\\\/corporativas\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Samsung Epis Holdings informa resultados financeiros do quarto trimestre e do ano fiscal de 2025\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/ocanal.com\\\/noticias\\\/corporativas\\\/#website\",\"url\":\"https:\\\/\\\/ocanal.com\\\/noticias\\\/corporativas\\\/\",\"name\":\"Ocanal Not\u00edcias Corporativas - Empresariais, comunicados e neg\u00f3cios\",\"description\":\"Tudo sobre o mercado empresarial, comunicados e neg\u00f3cios\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/ocanal.com\\\/noticias\\\/corporativas\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"pt-BR\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/ocanal.com\\\/noticias\\\/corporativas\\\/#\\\/schema\\\/person\\\/24f7b50e924d81f1023b69582993c0ff\",\"name\":\"DINO\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/ca8348556b3dfd41c825da9ac5643583f369a1092022fb6057420d716f02be0c?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/ca8348556b3dfd41c825da9ac5643583f369a1092022fb6057420d716f02be0c?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/ca8348556b3dfd41c825da9ac5643583f369a1092022fb6057420d716f02be0c?s=96&d=mm&r=g\",\"caption\":\"DINO\"},\"url\":\"https:\\\/\\\/ocanal.com\\\/noticias\\\/corporativas\\\/author\\\/dino\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Samsung Epis Holdings informa resultados financeiros do quarto trimestre e do ano fiscal de 2025 - Ocanal Not\u00edcias Corporativas - Empresariais, comunicados e neg\u00f3cios","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ocanal.com\/noticias\/corporativas\/samsung-epis-holdings-informa-resultados-financeiros-do-quarto-trimestre-e-do-ano-fiscal-de-2025\/","og_locale":"pt_BR","og_type":"article","og_title":"Samsung Epis Holdings informa resultados financeiros do quarto trimestre e do ano fiscal de 2025 - Ocanal Not\u00edcias Corporativas - Empresariais, comunicados e neg\u00f3cios","og_description":"A Samsung Epis Holdings (KRX: 0126Z0), empresa de investimentos dedicada a inova\u00e7\u00f5es em biofarmac\u00eautica e biotecnologia, anunciou hoje seus resultados financeiros para o quarto trimestre e o ano fiscal de 2025. &#8220;Estamos muito satisfeitos em anunciar um grande crescimento nas vendas no acumulado do ano, em nossos primeiros resultados financeiros ap\u00f3s a cis\u00e3o. Nosso crescimento [&hellip;]","og_url":"https:\/\/ocanal.com\/noticias\/corporativas\/samsung-epis-holdings-informa-resultados-financeiros-do-quarto-trimestre-e-do-ano-fiscal-de-2025\/","og_site_name":"Ocanal Not\u00edcias Corporativas - Empresariais, comunicados e neg\u00f3cios","article_published_time":"2026-01-26T15:29:44+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260125344665r1&amp;sid=brdno&amp;distro=ftp","type":"","width":"","height":""}],"author":"DINO","twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"DINO","Est. tempo de leitura":"7 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ocanal.com\/noticias\/corporativas\/samsung-epis-holdings-informa-resultados-financeiros-do-quarto-trimestre-e-do-ano-fiscal-de-2025\/#article","isPartOf":{"@id":"https:\/\/ocanal.com\/noticias\/corporativas\/samsung-epis-holdings-informa-resultados-financeiros-do-quarto-trimestre-e-do-ano-fiscal-de-2025\/"},"author":{"name":"DINO","@id":"https:\/\/ocanal.com\/noticias\/corporativas\/#\/schema\/person\/24f7b50e924d81f1023b69582993c0ff"},"headline":"Samsung Epis Holdings informa resultados financeiros do quarto trimestre e do ano fiscal de 2025","datePublished":"2026-01-26T15:29:44+00:00","mainEntityOfPage":{"@id":"https:\/\/ocanal.com\/noticias\/corporativas\/samsung-epis-holdings-informa-resultados-financeiros-do-quarto-trimestre-e-do-ano-fiscal-de-2025\/"},"wordCount":1372,"image":{"@id":"https:\/\/ocanal.com\/noticias\/corporativas\/samsung-epis-holdings-informa-resultados-financeiros-do-quarto-trimestre-e-do-ano-fiscal-de-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260125344665r1&amp;sid=brdno&amp;distro=ftp","articleSection":["Not\u00edcias Corporativas"],"inLanguage":"pt-BR"},{"@type":"WebPage","@id":"https:\/\/ocanal.com\/noticias\/corporativas\/samsung-epis-holdings-informa-resultados-financeiros-do-quarto-trimestre-e-do-ano-fiscal-de-2025\/","url":"https:\/\/ocanal.com\/noticias\/corporativas\/samsung-epis-holdings-informa-resultados-financeiros-do-quarto-trimestre-e-do-ano-fiscal-de-2025\/","name":"Samsung Epis Holdings informa resultados financeiros do quarto trimestre e do ano fiscal de 2025 - Ocanal Not\u00edcias Corporativas - Empresariais, comunicados e neg\u00f3cios","isPartOf":{"@id":"https:\/\/ocanal.com\/noticias\/corporativas\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ocanal.com\/noticias\/corporativas\/samsung-epis-holdings-informa-resultados-financeiros-do-quarto-trimestre-e-do-ano-fiscal-de-2025\/#primaryimage"},"image":{"@id":"https:\/\/ocanal.com\/noticias\/corporativas\/samsung-epis-holdings-informa-resultados-financeiros-do-quarto-trimestre-e-do-ano-fiscal-de-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260125344665r1&amp;sid=brdno&amp;distro=ftp","datePublished":"2026-01-26T15:29:44+00:00","author":{"@id":"https:\/\/ocanal.com\/noticias\/corporativas\/#\/schema\/person\/24f7b50e924d81f1023b69582993c0ff"},"breadcrumb":{"@id":"https:\/\/ocanal.com\/noticias\/corporativas\/samsung-epis-holdings-informa-resultados-financeiros-do-quarto-trimestre-e-do-ano-fiscal-de-2025\/#breadcrumb"},"inLanguage":"pt-BR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ocanal.com\/noticias\/corporativas\/samsung-epis-holdings-informa-resultados-financeiros-do-quarto-trimestre-e-do-ano-fiscal-de-2025\/"]}]},{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/ocanal.com\/noticias\/corporativas\/samsung-epis-holdings-informa-resultados-financeiros-do-quarto-trimestre-e-do-ano-fiscal-de-2025\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260125344665r1&amp;sid=brdno&amp;distro=ftp","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260125344665r1&amp;sid=brdno&amp;distro=ftp"},{"@type":"BreadcrumbList","@id":"https:\/\/ocanal.com\/noticias\/corporativas\/samsung-epis-holdings-informa-resultados-financeiros-do-quarto-trimestre-e-do-ano-fiscal-de-2025\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"In\u00edcio","item":"https:\/\/ocanal.com\/noticias\/corporativas\/"},{"@type":"ListItem","position":2,"name":"Samsung Epis Holdings informa resultados financeiros do quarto trimestre e do ano fiscal de 2025"}]},{"@type":"WebSite","@id":"https:\/\/ocanal.com\/noticias\/corporativas\/#website","url":"https:\/\/ocanal.com\/noticias\/corporativas\/","name":"Ocanal Not\u00edcias Corporativas - Empresariais, comunicados e neg\u00f3cios","description":"Tudo sobre o mercado empresarial, comunicados e neg\u00f3cios","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ocanal.com\/noticias\/corporativas\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"pt-BR"},{"@type":"Person","@id":"https:\/\/ocanal.com\/noticias\/corporativas\/#\/schema\/person\/24f7b50e924d81f1023b69582993c0ff","name":"DINO","image":{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/secure.gravatar.com\/avatar\/ca8348556b3dfd41c825da9ac5643583f369a1092022fb6057420d716f02be0c?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/ca8348556b3dfd41c825da9ac5643583f369a1092022fb6057420d716f02be0c?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/ca8348556b3dfd41c825da9ac5643583f369a1092022fb6057420d716f02be0c?s=96&d=mm&r=g","caption":"DINO"},"url":"https:\/\/ocanal.com\/noticias\/corporativas\/author\/dino\/"}]}},"_links":{"self":[{"href":"https:\/\/ocanal.com\/noticias\/corporativas\/wp-json\/wp\/v2\/posts\/46162","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ocanal.com\/noticias\/corporativas\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ocanal.com\/noticias\/corporativas\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ocanal.com\/noticias\/corporativas\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/ocanal.com\/noticias\/corporativas\/wp-json\/wp\/v2\/comments?post=46162"}],"version-history":[{"count":0,"href":"https:\/\/ocanal.com\/noticias\/corporativas\/wp-json\/wp\/v2\/posts\/46162\/revisions"}],"wp:attachment":[{"href":"https:\/\/ocanal.com\/noticias\/corporativas\/wp-json\/wp\/v2\/media?parent=46162"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ocanal.com\/noticias\/corporativas\/wp-json\/wp\/v2\/categories?post=46162"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ocanal.com\/noticias\/corporativas\/wp-json\/wp\/v2\/tags?post=46162"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}